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Neuropeptides are known to be important signaling molecules
in several neural systems of the pond snail Lymnaea stagnalis.
Although the functions of these peptides have been studied in
many neurons, the nature of the postsynaptic signal transduc-
tion is mainly unknown. The cloning and characterization of
neuropeptide receptors in Lymnaea thus would be very valu-
able in further elucidating peptidergic pathways. Indirect evi-
dence suggests that these neuropeptides operate via
G-protein-coupled mechanisms indicating the presence of
G-protein-coupled receptors as the initial postsynaptic targets.
Here we describe the cloning of a neuropeptide receptor from
Lymnaea and the isolation of an endogenous ligand. This pep-
tide, PSFHSWSamide, belongs to the leucokinin family of pep-
tides, and, thus, this Lymnaea receptor is the first example of a
leucokinin-like neuropeptide receptor, representing a new sub-
family of G-protein-coupled neuropeptide receptors.
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Leucokinins comprise a family of peptides that are found in the
CNS of insects and have been shown to be involved in diuresis
(Hayes et al., 1989; Coast et al., 1990). For instance, leucokinin
VIII significantly increases the rates of transepithelial NaCl, KCl,
and water secretion in Malpighian tubules of the yellow fever
mosquito Aedes aegypti (Pannabecker et al., 1993). The leucoki-
nins were first isolated from the cockroach through their ability to
induce cockroach hindgut contraction (Holman et al., 1986a,b,
1987a,b); subsequently, leucokinin-related peptides were found in
the cricket (Holman et al., 1990) and the locust (Schoofs et al.,
1992), all through the use of the hindgut bioassay. To date, 23
members of this family have been isolated: eight from the cock-
roach, five from the cricket Acheta domesticus, one from the locust
Locusta migratoria, three from the mosquito Culex Salinarius
(Clottens et al., 1993), three from the mosquito Aedes aegpti
(Veenstra, 1994), and three from the earworm Helicoverpa zea
(Blackburn et al., 1996). Immunocytochemistry has been used to
determine the anatomical location of leucokinins and leucokinin-
related peptides in insects, showing then to be in many areas of
the CNS (Lundquist et al., 1993; Nassel, 1993; Chen et al., 1994).
They have not yet been isolated from any other species, although
immunocytochemical studies using antisera raised to insect leu-
cokinins have indicated the presence of leucokinin-like peptides
in the CNS of the parasitic nematode Ascaris suum (Smart et al.,
1993), the spider Cupiennius salei (Schmid and Becherer, 1996),
and also in the mollusc Helix pomata (Elekes et al., 1994).
It is likely that the leucokinins and leucokinin-related peptides
constitute an important group of peptides in insects and inverte-
brates in general, considering their myotropic actions and involve-
ment in the control of water and electrolyte levels. Further studies
on their function are hampered by a paucity of data regarding the
postsynaptic sites of action; hence, the identification and charac-
terization of a leucokinin receptor would be of great value with
respect to this. The CNS of the pond snail Lymnaea stagnalis is
one of the best understood systems in terms of defined neural
networks and their relation to behavior, especially with respect to
neuropeptides (Benjamin and Burke, 1994); thus, we have at-
tempted to use this animal to characterize neuropeptide recep-
tors. Molecular cloning techniques were used to isolate cDNAs
encoding neuropeptide receptors from the CNS of Lymnaea. One
of these cDNAs, designated GRL104, encoded a protein that had
features previously described for other neuropeptide receptors.
GRL104 was expressed in stably transfected CHO-K1 cells, and
the peptide ligand was identified by the novel use of a multistep
HPLC approach, together with a functional calcium assay. The
peptide sequence was deduced to be PSFHSWSamide. When this
peptide was analyzed for sequence homology against a protein
database, it showed very high homology to the leucokinin family
of peptides, especially leucokinins IV and VI, with five of the last
six C-terminal residues being identical to the purified Lymnaea
peptide. This is the first report of a leucokinin-related peptide
being isolated from the CNS of an animal other than insects.
Some of this work has been presented previously in abstract
form (Tensen et al., 1994a).
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MATERIALS AND METHODS
Animals. Adult Lymnaea stagnalis (shell height 28–34 mm) were bred in
the laboratory under standard conditions.
Molecular procedures. Standard procedures were performed as de-
scribed by Sambrook et al. (1989). Restriction enzymes were purchased
from NBL (UK) or Boehringer Mannheim (Indianapolis, IN). Synthetic
oligonucleotides were synthesized on an ABI 380A synthesizer.
Polymerase Chain Reaction (PCR). PCR reactions were performed in
100 ml volumes containing 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM
MgCl2, 0.01% gelatin, 200 mM each dNTP, and 5–100 pmol of primers in
a Perkin-Elmer (Norwalk, CT) 9600 thermal cycler, using 1 U AmpliTaq
(Perkin-Elmer) or 0.2 U of SuperTaq (HT Biotechnologies, Cam-
bridge, UK)
cDNA library screening. Total RNA isolated from Lymnaea CNS was
converted into first strand cDNA using oligo(dT) Dynabeads (Dynal,
Oslo, Norway) and reverse transcription. Two primers were synthesized
corresponding to DNA sequences within conserved regions of transmem-
brane (TM) III and TM VI of many G-protein-coupled receptors (Libert
et al., 1989) [sense (S1) 59-CCGGATCCG(CT)(GC)AT(CT)(GA)-
(GC)(GC)IT(GT)GAC(CA)G(GC)TA-39; antisense (A1) 59-ACGAAT-
TCGG(GC)(CA)ICCA(GA)CAGAI(GC)(GA)(CT)(GA)AA-39]. These
were used in a PCR reaction under the following conditions: denaturation
at 968C for 10 min and then 48 cycles at 948C for 40 sec, 508C for 2 min,
and 728C for 3 min. Multiple PCR products were generated, and those of
the expected size (400–800 bp) were recovered from an agarose gel with
a pipette tip and reamplified in 32 cycles under identical conditions. The
total PCR mix was cloned in pBluescript II KS1 (Stratagene, La Jolla,
CA) for sequence analysis. Oligonucleotides based on these sequences
were used as primers in a PCR-based screening (Bloem and Yu, 1990) of
a lZAP II Lymnaea CNS cDNA library, modified as described previously
(Tensen et al., 1994b). Approximately 106 independent clones, amplified
in 10 aliquots of 105 original clones each, were constructed from poly(A1)
mRNA from Lymnaea CNS using a commercial cDNA synthesis [with
oligo (dT) priming] and cloning system according to the manufacturer’s
instructions. To isolate the corresponding full-length cDNA clones, we
excised cDNA inserts from these clones in vivo as phagemids and se-
quenced them. DNA sequences were determined from both strands,
using the dideoxy chain termination method (Sanger et al., 1977) with
denatured double-stranded DNA as a template and using the Sequenase
DNA sequencing kit (United States Biochemicals, Cleveland, OH). Au-
tomated sequencing was also performed with an ABI 373 automated
DNA sequencer. One clone, GRL104, showed high identical amino acid
homology (30%) to the neuropeptide Y receptor when the GenBank
database was screened.
Transfection of GRL104 into CHO-K1 cells. A Kozak optimal ribosomal
binding consensus sequence (59 TTTGGATCCGCCATGGCTCAAA-
TCGAGTCGATGTCCG 39; the start ATG is highlighted in bold) was
incorporated, using PCR, around the presumed start ATG (Kozak, 1986)
of the Lymnaea receptor sequence. Then this modified sequence was
cloned into the BamHI/XbaI sites of the mammalian expression vector
pcDNA1/neo (Invitrogen, San Diego, CA), which contains a cytomega-
lovirus promoter, an SV40 origin of replication, and the neomycin resis-
tance gene. The resulting expression construct, pcD104, was transfected
into CHO-K1 cells by lipofection with Lipofectin Reagent (Life Technol-
ogies, Gaithersburg, MD) according to the manufacturer’s instructions,
and stably expressing CHO-K1 clones were generated by continuous
selection with 400 mg/ml of the neomycin analog G-418 in DMEM
supplemented with 10% fetal calf serum and 1% glutamine.
Assay for the ligand to GRL104. CHO-K1 cells stably transfected with
pcD104 were resuspended in PBS containing 1 mM CaCl2 at a concen-
tration of 2 3 106 cells/ml. Fura-2-acetoxymethyl ester (Molecular
Probes, Eugene, OR) was added to the cells at a final concentration of 1
mM. The cells were kept at 48C for 60 min to allow the Fura-2 ester to
penetrate. The cells were washed with PBS three times and then resus-
pended in PBS containing 1 mM CaCl2 and 0.1% BSA at a concentration
of 2 3 106 cells/ml. The cells were kept on ice until the fluorescence assay
(a time gap of no more than 10 min). One milliliter of cell suspension was
warmed rapidly to 378C in a quartz cuvette, which was placed in a heated
cuvette chamber containing an integral magnetic stirrer. The cells were
stirred constantly during the experiments. The fluorescence spectropho-
tometer (Beckman, Fullerton, CA) was set to excite at 340 nm and
monitor emission at 510 nm, and fluorescence changes were recorded on
a chart recorder running at 10 cm/min. The slit width was 10 nm, and the
response time was two seconds. Dissolved ligands or HPLC fractions
were added to the cell suspension; fluorescence responses, if they oc-
curred, were measured immediately. To establish the maximum and
minimum amounts of fluorescence in each assay, we added Triton X-100
to achieve a final concentration of 0.1% and then EGTA to achieve a final
concentration of 10 mM. Intracellular calcium concentrations were quan-
titated with equations described by Grynkiewicz et al. (1985).
Extraction and purification of lymnokinin. Five hundred CNS were
dissected, collected on dry ice, and stored at 2608C until use. They were
homogenized in an all-glass Elvehem-Potter homogenizer in 5 ml of 0.1
M acetic acid over ice, boiled for 5 min, and centrifuged at 48C for 5 min.
The supernatant was filtered and applied to a C18 solid-phase extraction
column (Supelclean, Supelco, Bellefonte, PA), and bound material was
eluted with a mixture of 60% acetonitrile and 7.0 mM trifluoroacetic acid
(TFA). The crude peptide fraction was subjected immediately to high-
performance gel permeation chromatography (HPGPC), which consisted
of applying the crude peptide extract to Protein-Pak columns I-125 and
I-300 connected in series (Water Associates, Milford, MA), using a
running solvent of 7 mM TFA in 30% CH3CN. The liquid chromato-
graphic system (Waters Associates) consisted of an M-720 system con-
troller, an M-730 data module, an M-6000A solvent delivery system, and
an M-441 UV/VIS absorbance detector. Thirty fractions were collected,
lyophilized, and then resuspended in 500 ml of water. Bioactive fractions
were pooled and subjected to reverse-phase HPLC (rpHPLC). First we
used a Nucleosil C18 column (250 3 4.6 mm), applying a discontinuous
linear gradient of water and CH3CN in 7.5 mM TFA (10 min 0% CH3CN
and then 0–60% CH3CN over 60 min). Approximately 60 fractions were
collected, lyophilized, and redissolved in distilled water. Bioactive frac-
tions were pooled and subjected to a second round of rpHPLC using a
narrow bore Nucleosil column (250 3 2.1 mm), applying a discontinuous
linear gradient of water and CH3CN in 0.05% HCl (10 min 0% CH3CN
and then 0–60% CH3CN over 60 min). Bioactive fractions from this
rpHPLC run were rechromatographed with the same column and sol-
vents but with a shallower gradient (12% CH3CN over 10 min and then
12–24% CH3CN over 40 min) using a Gynotek system that consisted of a
480G gradient pump, a model III channel on-line degasser, and a UVD
320S photo-diode array detector.
Peptide sequence determination and synthesis. Amino acid sequences
were determined with a pulse liquid automatic sequencer (model 473A,
Applied Biosystems, Foster City, CA) as described previously (Li et al.,
1993). Peptides were synthesized by Fluorenylmethoxycarbonyl and
t-butoxycarbonyl chemistry on an ABI 432A peptide synthesizer.
Mass spectrometry.Mass spectral analyses were performed on a Quattro-II
triple-quadrupole mass spectrometer equipped with an electrospray source
(Micromass). The first quadrupole (ms 1) was used for the mass measure-
ment of the peptide and the parent ion selection for tandem mass spectrom-
etry. For parent ion selection, the first quadrupole was set to transmit a mass
window of 2.5 Da. The (M 1 H)21 ion species was selected for fragmenta-
tion. The collision cell pressure was set at 3.3 mB throughout the run, and the
collision voltage was set to 15 V. Argon was used as the collision gas. The
quadrupole analyzer (ms 2) was scanned over the range of 50–1000 mass to
charge (m/z). The resolution was set to ;1000.
RESULTS
cDNA cloning
The degenerate oligonucleotide primers S1 and A1 were used to
obtain a PCR product, named GRL104 (see Materials and Meth-
ods). GRL104, when analyzed and compared against the GenBank
protein database, showed high (25–32%) identical amino acid ho-
mology to a number of G-protein-coupled neuropeptide receptors.
An oligonucleotide primer specific to GRL104 was used in conjunc-
tion with pBluescript forward and reverse arm primers in a PCR
reaction on the cDNA CNS library to generate a larger GRL104
PCR product containing the full-length 59 region. If Lymnaea neu-
ropeptide receptors are similar to those cloned from other species,
then the distance from the exact primer to the 59 end should be in the
region of 1000–1500 bp. Bands in this size range were cloned into a
pBluescript plasmid and transformed into DH5a. Plasmids isolated
from two colonies were fully sequenced to identify the start methi-
onine of GRL104. A candidate for a start methionine was found in
one of the GRL104 clones, and this clone was isolated from the
library by PCR screening (Bloem andYu, 1990). TheDNA sequence
of the clone GRL104 is shown in Figure 1.
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Analysis of GRL104
The complete sequence of GRL104 was entered into DNASTAR so
that it could be analyzed for open reading frames (ORF). A methi-
onine at position 374 signaled the beginning of the longest ORF, of
1287 bp, which translates into 429 amino acids, and this was taken to
be the coding ORF (Fig. 1). To obtain further information about
GRL104, we analyzed the amount of the sequence homology be-
tween the full-length amino acid sequence of GRL104 and other
G-protein-coupled receptors. The full amino acid sequence resulting
from the ORF in the cDNA GRL104 was compared against protein
Figure 1. Nucleotide and deduced amino acid
sequence of Lymnaea GRL104 receptor cDNA
cloned in pBluescript BS2. A methionine at posi-
tion 374 indicates the start of the open reading
frame of 1287 bp, which translates into 429 amino
acids. Putative transmembrane regions are under-
lined and labeled I–VII. Cysteines suspected of
being involved in a cysteine bridge between extra-
cellular loops 2 and 3 are indicated by filled circles.
Arrowheads indicate possible N-linked glycosyla-
tion sites. The nucleotide sequence for GRL104
has been deposited into GenBank, accession num-
ber U84499.
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databases with the DNASTAR program Proscan, which uses the
algorithm of Lipman and Pearson to compare amino acid sequence
similarities between proteins (Lipman and Pearson, 1985). The pro-
tein database search for GRL104 yielded neuropeptide receptors as
the top 20 most similar proteins. Specifically, the rat neuropeptide Y
(NPY) Y1 receptor was the most similar, with the exact amino acid
homology being 32.4% on a 355 amino acid overlap. When the
amino acid sequence was analyzed for its hydrophobicity profile
(Kyte andDoolittle, 1982), it was found that there were seven regions
of hydrophobicity that could be transmembrane domains. There
were several domains that had particularly high homology to the rat
NPY receptor; these areas closely correlated with the hydrophobic,
and thus possibly the transmembrane, domains. In addition to the
seven transmembrane domains, GRL104 has a very short extracel-
lular region of only 45 amino acids. At the C-terminal cytosolic end
of the receptor there is an 89 amino acid stretch.
Comparisons were made between some of the transmembrane
regions in a selection of classical neurotransmitter receptors,
neuropeptide receptors, and this Lymnaea receptor GRL104. This
alignment is shown in Figure 2. GRL104 shows sequence homol-
ogy to both classical and peptide G-protein-coupled receptors,
e.g., the serine and aspartate arginine tyrosine triplet in TM III,
the isoleucine and proline in TM IV, the phenylalanine trypto-
phan and proline in TM VI, and the tryptophan, the asparagine
proline doublet, and the tyrosine in TM VII. Further sequence
homology is present between GRL104 and neuropeptide recep-
tors alone in that there is a conserved leucine in TM VI, a
conserved alanine in TM IV, and a conserved tyrosine in TM VII.
These alignments indicated that GRL104 was likely to be a
G-protein-coupled neuropeptide receptor.
Generation of stable CHO-K1 cell lines
GRL104 was modified as described in Materials and Methods, and
the resulting plasmid, pcD104, was used in transfection experiments.
CHO-K1 cells were transfected with pcD104, and nine clones were
picked for further experiments. To confirm that the plasmid pcD104
had been integrated into the CHO genomic DNA, we analyzed some
of these cell lines by PCR. Sense and antisense primers at the
extreme 59 and 39 ends of the ORF of pcD104 were used to attempt
to amplify the receptor DNA sequence from the cell lines. All the
CHO lines tested, KC2, KC4, KC5, KC6, KC7, and KC9, gave PCR
products of ;1300 bp, which is the expected size for the GRL104
transcript (Fig. 3). From this it could be inferred that the transfected
CHO cells had incorporated pcD104 into the CHO genome. These
clones were now called GRL104 CHO cell lines, because pcD104
was carrying GRL104 receptor DNA.
Expression of GRL104 in mammalian cells and
identification of the endogenous ligand
On binding to ligands, many G-protein-coupled receptors, including
peptide receptors, link via G-proteins in a secondmessenger cascade,
resulting in an increase in intracellular calcium concentration. This
can be used to assay for ligands to GRL104. The first stage was to
challenge the GRL104 CHO cell lines with a CNS peptide extract
from Lymnaea. Peptides from 500 Lymnaea CNS were extracted and
purified through a C18 solid-phase extraction column. All nine
GRL104 CHO cell lines, together with untransfected CHO cells,
were loaded with Fura-2 and challenged with an amount of crude
Figure 3. PCR analysis of CHO cell lines stably transfected with pcD104,
using primers specific to pcD104. Lanes 1–6 contain PCR products from
CHO cell lines KC2, KC4, KC5, KC6, KC7, and KC9. Lane 7 is a negative
control using untransfected CHO-K1 cells as template. Lane 8 is a control
PCR reaction with no template. Lane M contains size markers generated
from l bacteriophage cut by HindIII.
Figure 2. Shown are transmembrane (TM ) region amino acid alignments betweenGRL104 and other G-protein-coupled receptors: SK, human substance
K receptor (Gerard et al., 1990); SP, rat substance P receptor (Yokota et al., 1989); NPY, human NPY Y1 receptor (Herzog et al., 1992); Musc, human
m1 ACh receptor (Peralta et al., 1987); DA, human D1 dopamine receptor (Dearry et al., 1990); 5HT, human 5HT1d receptor (Hamblin and Metcalf,
1991). Shaded boxes indicate residues that are conserved among both classical and peptide receptors. Nonshaded boxes indicate residues that are conserved
only among peptide receptors.
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peptides equivalent to two CNS. Changes in intracellular calcium
were monitored by studying changes in fluorescence. Five of the nine
clones responded to the peptide extract, although the other four did
not respond. Untransfected CHO cells did not respond to Lymnaea
CNS peptide extracts. These results suggested that in over 50% of
the stable cell lines, where the receptor construct had incorporated
into the CHO genome, it was transcribed and, subsequently, trans-
lated. Moreover, the results demonstrate that the GRL104 receptor
in CHO cells was able to couple to a secondmessenger system, which
had the effect of increasing intracellular calcium. The CHO clone
GLR104 KC6 was used in subsequent assays because, of the nine
GRL104 CHO stable cell lines, it yielded the largest rise in intracel-
lular calcium when challenged with the CNS peptide extract.
Figure 4 shows the four steps of the HPLC procedure. Fractions
23 and 24 from the gel permeation separation were bioactive in
the calcium assay (Fig. 4A) and so were combined and run on the
rpHPLC column in step 2 (Fig. 4B). Fraction 29 was positive and
further purified in step 3 on a reverse-phase HPLC column (Fig.
4C). Fraction 37 from this run generated a rise in intracellular
calcium concentration, and fraction 36 gave a much smaller rise.
A final rpHPLC purification run (step 4, Fig. 4D) was performed
on pooled fractions 36 and 37 (from step 3), which resolved into
two peaks from which it was possible to obtain peptide sequence
from both peaks. Edman sequencing revealed one of the peptides
to be GDPFLR (the large peak). It is very likely that this peptide
represents the previously reported GDPFLRFamide, in which the
C-terminal amino acid was washed off from the sequencing filter
and cannot be detected. The other peptide (the small peak) was
deduced to have the sequence PSFHSWX. As with GDPFLRF-
amide, the first six residues could be assigned unambiguously;
however, the final residue in this peptide was evident only as a
small peak (again as with GDPFLRFamide the C-terminal resi-
due also may have been washed off) and could not be assigned
with complete confidence. The sequence PSFHSW was run
through a peptide database to establish whether it had any ho-
mology to known peptides. This search produced a family of eight
peptides, all eight amino acids long, called the leucokinins (Table
1); therefore, we designated the Lymnaea peptide lymnokinin. In
an attempt to confirm the sequence of lymnokinin, we isolated
and sequenced a new batch of peptide. On this occasion closer
inspection of the sequencing data indicated the presence of a (C-
terminal) serine residue. To ascertain the sequence of the peptide
unequivocally, we subjected it to tandem mass spectrometric
analysis. Figure 5 shows that the peptide is PSFHSWSamide.
One of the potential ligands, GDPFLRFamide, was unable to
stimulate GRL104 even at micromolar concentrations (data not
shown). Synthetic lymnokinin, on the other hand, was able to stim-
ulate CHO cells expressing GRL104 at physiological concentrations,
and a dose–response experiment was performed (Fig. 6). Lymnoki-
nin had an EC50 of 1.14 nM, which is similar to other neuropeptide
potencies. For instance, SP has an IC50 of ;1 nM (Hershey and
Krause, 1990) for the NK-1 receptor. Because it seemed likely that
lymnokinin was indeed a member of the leucokinin family, it was
possible that other members of the family also were able to elicit
calcium responses in CHO cells expressing GRL104. Three commer-
cial preparations of the insect leucokinins were tested on KC6.
Leucokinin IV and leucokinin VI, both of which have five of the last
six C-terminal amino acids in common with lymnokinin (Table 1),
were able to elicit an increase in calcium concentration in GRL104
KC6 CHO cells at 100 nM or above, i.e., a 100-fold lower potency
than lymnokinin, whereas leucokinin V, which only has three amino
acids in common with lymnokinin (Table 1), was less potent, being
Table 1.
Species Peptide name Amino acid sequence Reference
Lymnaea stagnalis Lymnokinin PSFHSWS-amide This paper
Leucophaera maderae Leucokinin I DPAFNSWG-amide Holman et al., 1986a
Leucokinin II DPGFSSWG-amide Holman et al., 1986a
Leucokinin III DQGFNSWG-amide Holman et al., 1986b
Leucokinin IV DASFHSWG-amide Holman et al., 1986b
Leucokinin V GSGFSSWG-amide Holman et al., 1987a
Leucokinin VI pESSFHSWG-amide Holman et al., 1987a
Leucokinin VII DPAFSSWG-amide Holman et al., 1987b
Leucokinin VIII GADFYSWG-amide Holman et al., 1987b
Acheta domesticus Achetakinin I SGADFYPWG-amide Holman et al., 1990
Achetakinin II AYFSPWG-amide Holman et al., 1990
Achetakinin III ALPFSPWG-amide Holman et al., 1990
Achetakinin IV NFKFNPWG-amide Holman et al., 1990
Achetakinin V AFHSWG-amide Holman et al., 1990
Locusta migratoria Locustakinin AFSSWG-amide Schoofs et al., 1992
Culex salinarius CDP I NPFHSWG-amide Clottens et al., 1993
CDP II NNANVFYPWG-amide Clottens et al., 1993
CDP III TKYVSKQFFSWG-amide Clottens et al., 1993
Aedes aegypti I NSKYVSKQKFYSWG-amide Veenstra, 1994
II NPFHAYFSAWG-amide Veenstra, 1994
III NNPNVFYPWG-amide Veenstra, 1994
Helicoverpa zea Helicokinin I YFSPWG-amide Blackburn et al., 1995
Helicokinin II VRFSPWG-amide Blackburn et al., 1995
Helicokinin III KVKFSAWG-amide Blackburn et al., 1995
Amino acid sequences of purified lymnokinin and comparison with the leucokinins and leucokinin-related peptides that have been isolated and sequenced from various species.
Amino acids that are conserved throughout the family are in bold.
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Figure 4. Purification of the endogenous ligand for GRL104. All assays were performed on a CHO cell line that had been stably transfected with pcD104
cDNA (CHO cell line GRL104 KC6). The top of each panel, A–C, gives the chromatogram for the HPLC purification indicated. A1, HPGPC fractionation
of an extract of 500 Lymnaea brains; B1, rpHPLC fractionation of combined fractions 23 and 24 from A; C1, rpHPLC fractionation of fraction 29 from
B. D, rpHPLC fractionation of combined fractions 36 and 37 from C. The bottom of each panel, A–C, shows the effect of the indicated HPLC fractions
on intracellular calcium levels in the CHO cell line GRL104 KC6, using 2, 4, and 8 CNS equivalents for A2, B2, B3, C2, and C3, respectively. x-Axis numbers
indicate HPLC fraction number. The calcium increases were calculated as increases in concentration above basal levels. On each HPLC fractionation,
A2 shows the two fractions (of 33) that were active (mean of two determinations), B3 shows the fraction (of 54) that was active (mean of two
determinations), and C3 shows the two fractions (of 45) that were active (one determination only to conserve enough of the fraction for the next stage
of HPLC, seen in D).
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able to elicit a response at 1 mM or above (data not shown). On the
other hand, PSFHSWGamide, which is identical to lymnokinin apart
from the Gamide (which is present in the leucokinins), was as potent
as lymnokinin with an EC50 of 1.2 nM (data not shown). Several other
peptides (VIP, FLRFamide, FMRFamide, APGWamide, vasopres-
sin, substance P, substance K, eloidisin, and neuropeptide Y) were
tested on GRL104 but were unable to elicit any calcium response.
DISCUSSION
The leucokinin family of peptides (Table 1) has been the focus of
considerable interest since they were first isolated from the cock-
roach and, subsequently, in other insects such as the cricket, locust,
and mosquito. They have two main physiological effects on insects;
one is to increase hindgut motility in cockroaches (Holman et al.,
1986a,b, 1987a,b), and the other is an involvement in insect diuresis
(Hayes et al., 1989; Coast et al., 1990). It has been shown that
leucokinins have an effect on the transepithelial voltage and the fluid
secretion of isolatedMalpighian tubules of the yellow fever mosquito
Aedes aegypti, and this effect is speculated to be mediated by an
increase in chloride ion permeability of epithelial membranes (Hayes
et al., 1989; Pannabecker et al., 1993). Leucokinin-like peptides have
effects on the stomatogastric nervous system of the crab Cancer
borealis; this work shows that individual leucokinins were able to
excite the pyloric rhythm and also the DG neuron (which is involved
in the gastric mill rhythm), suggesting the presence of an as yet
uncharacterized endogenous leucokinin-like peptide in this species
Figure 5. Tandem mass spectrometric analysis of lymnokinin. Averaged daughter ion spectra of the purified lymnokinin, generated from the doubly
charged parent ion species (M 1 2H)21 of m/z 424 Da. The Roepstorff nomenclature is used to identify fragment ions (Roepstorff and Fohlman, 1984).
The y” ions are formed by charge retention on C-terminal fragments, and the a and b ions are formed on N-terminal fragments. The measured protonated
mass of the peptide [846.8 Da, as detected in stage 1 (ms 1) of the tandem MS analysis; data not shown] as well as the y”, a, and b ion series are in perfect
agreement with the calculated protonated masses of the peptide PSFHSWSamide (846.9 Da as detected in ms 1; data not shown) and the corresponding
y”, a, and b ion series. The asterisk represents a6
21, x-axis; m/z is mass to charge ratio.
Figure 6. Dose–response curve of the increase in intracellular calcium in
GRL104 KC6 CHO cells elicited by synthetic lymnokinin. The calcium
increases were calculated as increases in concentration above basal cal-
cium levels. Each data point is the mean of three separate determinations.
Error bars are 6 SD.
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(Blitz et al., 1995). InHelix, an antibody to leucokinin I stained many
neurons in the CNS, including interneurons and neurons that are
known to innervate peripheral organs, indicating that leucokinins
play a wide role in the CNS of molluscs (Elekes et al., 1994). The
identification and characterization of the molluscan leucokinin-
related receptor GRL104 described here is an important advance in
mapping leucokinin neuronal pathways and understanding the phys-
iological function of this family of peptides in molluscs and, poten-
tially, in other invertebrates. Work is currently in progress to localize,
in alternate sections of the Lymnaea CNS, the relationship between
the lymnokinin receptor-expressing cells (using in situ hybridization)
and lymnokinin (using an antiserum raised against leucokinin IV).
The G-protein-coupled superfamily of receptors (Probst et al.,
1992) is composed of a number of subfamilies, one of which is the
peptide receptor family. Members of this group include, for in-
stance, the NPY receptors and the tachykinin receptors, which
comprise further subfamilies of receptors. GRL104 was most
similar to neuropeptide receptors, especially to the rat NPY
receptor with 32% identical sequence homology. This amount of
homology indicates that GRL104 is very likely to be a neuropep-
tide receptor, but not a subtype of any known neuropeptide
receptor. This, in conjunction with the fact that none of the
tachykinins or NPY or any other peptide tested (except leucoki-
nins) were able to mobilize calcium in CHO cells transfected with
GRL104, indicates that GRL104 is the first example of a new
group of G-protein-coupled neuropeptide receptors.
Of the peptides tested, only PSFHSWSamide (lymnokinin) and
PSFHSWGamide were able to activate GRL104 at the nanomolar
level. We consider that lymnokinin is the endogenous ligand to
GRL104 because it was isolated from the CNS of Lymnaea, but we
cannot rule out that PSFHSWGamide also may be present in the
CNS of Lymnaea and a ligand for GRL104. Furthermore, it is
possible that other presumably lymnokinin-like peptides are in the
CNS of Lymnaea that are also ligands for GRL104. Efficacious
peptides present in the CNS at very low levels would not be isolated
using the above HPLC approach in which only 500 Lymnaea CNS
were used; it may be that, as in the case of the leucokinins, lymno-
kinin may be just one of a family of lymnokinin-like peptides. It is
interesting to note that members of the leucokinin group of peptides
also were able to activate GRL104. Two obvious candidates were
leucokinin IV and leucokinin VI, because they have five of the last six
C-terminal amino acids in common with the deduced sequence of
lymnokinin. These peptides activatedGRL104 at 500 nM. Apart from
the C-terminal residue, the only differences between lymnokinin and
leucokinin IV and leucokinin VI are that the latter two peptides have
one extra amino acid and that the amino acid at position seven is an
alanine for leucokinin IV and a serine for leucokinin VI, whereas for
lymnokinin it is a proline. One of the other members of the leuco-
kinin peptide family, leucokinin V, was tested on GRL104, eliciting
a functional response only at 1026 M. This comparatively lower
potency is perhaps not surprising considering that only three amino
acids were in common (Table 1). It is probable that the other
peptides shown in Table 1, apart from achetakinin V and culekinin-
depolarizing peptide (CDP) I, which share similar C-terminal regions
with lymnokinin, also would elicit a functional response in the mi-
cromolar range. In the light of the Gamide being invariant in the
leucokinin peptide family, PSFHSWGamide was also synthesized
and tested for functional efficacy with respect to GRL104. The fact
that PSFHSWGamide has a very similar potency to lymnokinin
indicates that the C-terminal residue may not be critical in that it can
be Gamide or Samide. This is perhaps not too surprising, because
glycine and serine are very similar. Other peptides with little or no
C-terminal sequence homology to lymnokinin were unable to elicit
any functional response. These data seem to suggest that lymnokinin
N-terminal residues are important for increased potency when cou-
pling to GRL104, with the C-terminal residues perhaps playing a
greater role in binding to the receptor. Further evidence indicating
the importance of the N-terminal region of neuropeptides with
respect to functional potency has been provided previously by struc-
ture–activity studies with leucomyosuppressin, a 10-amino-acid-long
peptide isolated from cockroach, which is able to inhibit spontaneous
contractions of visceral muscles (Nachman et al., 1993). A clear
relationship was found between C-terminal peptide content and
potency, with the last five C-terminal amino acids being the mini-
mum size for eliciting a functional response. As more residues were
added from the C-terminal end, potency increased. Binding studies
with both N- and C-terminally truncated lymnokinin analogs are
needed to determine whether N-terminal residues are responsible
for the increased potency and the C-terminal end for binding to
GRL104. Although not examined in the present work, the full
dose–response characteristics of the leucokinins with respect to
GRL104 also would be of interest regarding the relationship between
peptide structure and function.
An apparent difference by a factor ;50 is evident between
the potencies of the leucokinin-like peptides in the hindgut and
Malpighian tubule assays, and lymnokinin in the calcium as-
says, with CHO cells expressing GRL104 receptor protein. For
instance, the ED50 for achetakinin-I in the Malpighian tubule
assay is 7.5 3 10211 M (Coast et al., 1990), whereas the EC50
of lymnokinin with respect to GRL104 is 1.14 nM. This differ-
ence may indicate a combined hormonal /neurotransmitter role
for lymnokinin, as has been suggested for the leucokinins
(Muren et al., 1993). The fact that GRL104 was isolated from
a CNS cDNA library is in agreement for its being the receptor
for lymnokinin when this peptide is acting as a neurotransmit-
ter in the CNS of Lymnaea, and, as has been mentioned
previously, the EC50 of lymnokinin with respect to GRL104 is
in the range found for other peptide neurotransmitters.
Here we have described the cloning from Lymnaea of a
neuropeptide receptor, GRL104, for which the endogenous
ligand lymnokinin, a leucokinin-like peptide, has been isolated.
GRL104 represents the first example of a new subfamily of
neuropeptide receptors, the leucokinin-like peptide receptors.
Also presented here is the first example of the isolation of a
leucokinin-like peptide in a invertebrate other than an insect.
Molecular biological techniques such as PCR have enabled
many G-protein-coupled receptor sequences, characterized as
such purely on homology to known receptors, to be isolated.
Many of these receptors are, however, “orphans,” because the
nature of the endogenous ligands is unknown. Recently, an
approach using HPLC fractions on receptor-expressing cell
lines was used to identify a novel opiate ligand to an orphan
G-protein-coupled receptor, using a cAMP assay (Meunier et
al., 1995; Reinscheid et al., 1995). The approach described in
the present work (reported briefly previously, Tensen et al.,
1994a), which also uses multistep HPLC but this time uses as
the functional response an increase in intracellular calcium, is
a more general method for isolating an endogenous ligand to a
suspected G-protein-coupled receptor in that both cAMP and
PKC second messenger pathways result in an increase in intra-
cellular calcium. This approach should be valuable in identify-
ing the ligands to other orphan receptors.
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